Shares of Wave Life Sciences Ltd. (NASDAQ:WVE – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $13.17.
A number of research analysts have recently issued reports on the company. Wells Fargo & Company started coverage on Wave Life Sciences in a research report on Wednesday, May 15th. They set an “overweight” rating and a $11.00 target price on the stock. StockNews.com lowered shares of Wave Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Wave Life Sciences in a research note on Wednesday, June 26th. Finally, Mizuho reaffirmed an “outperform” rating and issued a $19.00 price target on shares of Wave Life Sciences in a research note on Tuesday, June 25th.
View Our Latest Research Report on WVE
Institutional Trading of Wave Life Sciences
Wave Life Sciences Price Performance
NASDAQ WVE opened at $5.85 on Thursday. The company has a market capitalization of $716.48 million, a PE ratio of -11.25 and a beta of -1.12. The company has a fifty day moving average of $5.73 and a 200 day moving average of $5.59. Wave Life Sciences has a 1 year low of $3.50 and a 1 year high of $7.67.
Wave Life Sciences (NASDAQ:WVE – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). The firm had revenue of $19.69 million for the quarter, compared to analysts’ expectations of $24.80 million. Wave Life Sciences had a negative return on equity of 1,395.99% and a negative net margin of 66.50%. During the same period last year, the company posted ($0.20) earnings per share. Research analysts expect that Wave Life Sciences will post -1.05 earnings per share for the current year.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Recommended Stories
- Five stocks we like better than Wave Life Sciences
- Financial Services Stocks Investing
- Top 3 Michael Burry Stock Picks to Watch in 2024
- How to Calculate Return on Investment (ROI)
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Stock Sentiment Analysis: How it Works
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.